Safety and Clinical Management Safety trials of GLP-1 RAs, including liraglutide, tirzepatide, and semaglutide (oral or subcutaneous), indicate that the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite
2/ What is Ozempic
They studied about 10,000 patients who had both kidney cancer and type 2 diabetes between 2005 and 2025
978 Bjrnvall, C
Semaglutide API manufacturers face several significant technical, regulatory, and commercial challenges
[2] [9] The Summary of Product Characteristics (SmPC) for Mounjaro does not list depression or mood changes as recognised side effects at present